The safety of rosiglitazone in the treatment of Type 2 diabetes

Sonal Singh, Yoon K. Loke

Research output: Contribution to journalArticle

Abstract

Background: Cardiovascular disease is the leading cause of mortality among adults with Type 2 diabetes. The thiazolidinediones including rosiglitazone are approved for the treatment of Type 2 diabetes on the basis of their ability to lower blood sugar and surrogate markers of cardiovascular disease. Objectives: To ascertain the cardiovascular, skeletal and hematologic safety profile of rosiglitazone. Methods: Synthesis of evidence from recent trials, systematic reviews, meta-analysis, regulatory documents and clinical trials registries of manufacturers. Conclusion: Rosiglitazone increases the risk of heart failure, myocardial infarction and fractures (in women) with Type 2 diabetes.

Original languageEnglish (US)
Pages (from-to)579-585
Number of pages7
JournalExpert Opinion on Drug Safety
Volume7
Issue number5
DOIs
StatePublished - Sep 2008
Externally publishedYes

Fingerprint

rosiglitazone
Type 2 Diabetes Mellitus
Safety
Cardiovascular Diseases
Thiazolidinediones
Registries
Blood Glucose
Meta-Analysis
Therapeutics
Heart Failure
Biomarkers
Myocardial Infarction
Clinical Trials
Mortality

Keywords

  • Cardiovascular adverse effects
  • Fractures
  • Heart failure
  • Myocardial infarction
  • Rosiglitazone
  • Safety

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

The safety of rosiglitazone in the treatment of Type 2 diabetes. / Singh, Sonal; Loke, Yoon K.

In: Expert Opinion on Drug Safety, Vol. 7, No. 5, 09.2008, p. 579-585.

Research output: Contribution to journalArticle

Singh, Sonal ; Loke, Yoon K. / The safety of rosiglitazone in the treatment of Type 2 diabetes. In: Expert Opinion on Drug Safety. 2008 ; Vol. 7, No. 5. pp. 579-585.
@article{c5536839970148c28c73ef6b2b9332f6,
title = "The safety of rosiglitazone in the treatment of Type 2 diabetes",
abstract = "Background: Cardiovascular disease is the leading cause of mortality among adults with Type 2 diabetes. The thiazolidinediones including rosiglitazone are approved for the treatment of Type 2 diabetes on the basis of their ability to lower blood sugar and surrogate markers of cardiovascular disease. Objectives: To ascertain the cardiovascular, skeletal and hematologic safety profile of rosiglitazone. Methods: Synthesis of evidence from recent trials, systematic reviews, meta-analysis, regulatory documents and clinical trials registries of manufacturers. Conclusion: Rosiglitazone increases the risk of heart failure, myocardial infarction and fractures (in women) with Type 2 diabetes.",
keywords = "Cardiovascular adverse effects, Fractures, Heart failure, Myocardial infarction, Rosiglitazone, Safety",
author = "Sonal Singh and Loke, {Yoon K.}",
year = "2008",
month = "9",
doi = "10.1517/14740338.7.5.579",
language = "English (US)",
volume = "7",
pages = "579--585",
journal = "Expert Opinion on Drug Safety",
issn = "1474-0338",
publisher = "Informa Healthcare",
number = "5",

}

TY - JOUR

T1 - The safety of rosiglitazone in the treatment of Type 2 diabetes

AU - Singh, Sonal

AU - Loke, Yoon K.

PY - 2008/9

Y1 - 2008/9

N2 - Background: Cardiovascular disease is the leading cause of mortality among adults with Type 2 diabetes. The thiazolidinediones including rosiglitazone are approved for the treatment of Type 2 diabetes on the basis of their ability to lower blood sugar and surrogate markers of cardiovascular disease. Objectives: To ascertain the cardiovascular, skeletal and hematologic safety profile of rosiglitazone. Methods: Synthesis of evidence from recent trials, systematic reviews, meta-analysis, regulatory documents and clinical trials registries of manufacturers. Conclusion: Rosiglitazone increases the risk of heart failure, myocardial infarction and fractures (in women) with Type 2 diabetes.

AB - Background: Cardiovascular disease is the leading cause of mortality among adults with Type 2 diabetes. The thiazolidinediones including rosiglitazone are approved for the treatment of Type 2 diabetes on the basis of their ability to lower blood sugar and surrogate markers of cardiovascular disease. Objectives: To ascertain the cardiovascular, skeletal and hematologic safety profile of rosiglitazone. Methods: Synthesis of evidence from recent trials, systematic reviews, meta-analysis, regulatory documents and clinical trials registries of manufacturers. Conclusion: Rosiglitazone increases the risk of heart failure, myocardial infarction and fractures (in women) with Type 2 diabetes.

KW - Cardiovascular adverse effects

KW - Fractures

KW - Heart failure

KW - Myocardial infarction

KW - Rosiglitazone

KW - Safety

UR - http://www.scopus.com/inward/record.url?scp=54449086845&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=54449086845&partnerID=8YFLogxK

U2 - 10.1517/14740338.7.5.579

DO - 10.1517/14740338.7.5.579

M3 - Article

VL - 7

SP - 579

EP - 585

JO - Expert Opinion on Drug Safety

JF - Expert Opinion on Drug Safety

SN - 1474-0338

IS - 5

ER -